An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma.
Acetates
/ chemistry
Adenocarcinoma
/ diagnostic imaging
Animals
Azepines
/ chemistry
Biomarkers, Tumor
Cell Line, Tumor
Contrast Media
Fibrin
/ chemistry
Fibronectins
/ chemistry
Gadolinium
/ chemistry
Humans
Magnetic Resonance Imaging
Male
Mice
Mice, Nude
Neoplasm Transplantation
Peptides
/ chemistry
Prostatic Neoplasms
/ diagnostic imaging
Protein Binding
Spectrometry, Mass, Electrospray Ionization
AAZTA
T1-weighted MRI
fibrin-fibronectin complex
prostate cancer
targeting peptide
Journal
Magnetic resonance in medicine
ISSN: 1522-2594
Titre abrégé: Magn Reson Med
Pays: United States
ID NLM: 8505245
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
11
04
2018
revised:
23
07
2018
accepted:
23
07
2018
pubmed:
27
9
2018
medline:
18
3
2020
entrez:
27
9
2018
Statut:
ppublish
Résumé
Prostate cancer (PCa) is the most widespread tumor affecting males in Western countries. We propose a novel MRI molecular tetrameric probe based on the heptadentate gadolinium (Gd)-AAZTA (6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid) that is able to in vivo detect PCa through the recognition of the fibrin-fibronectin (FB-FN) complex. The peptide CREKA (Cys-Arg-Glu-Lys-Ala), targeting the FB-FN complex in the reactive stroma of the tumor, was synthesized by solid phase peptide synthesis (SPPS) and conjugated to the tetramer dL-(Gd-AAZTA) CREKA-dL-(Gd-AAZTA) This study demonstrated the ability of the CREKA-dL-(Gd-AAZTA)
Substances chimiques
1,4-bis(hydroxycarbonylmethyl)-6-(bis(hydroxycarbonylmethyl))amino-6-methylperhydro-1,4-diazepine
0
Acetates
0
Azepines
0
Biomarkers, Tumor
0
Contrast Media
0
Fibronectins
0
Peptides
0
Fibrin
9001-31-4
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1935-1946Subventions
Organisme : AIRC Investigator Grant
ID : IG-14565
Pays : International
Informations de copyright
© 2018 International Society for Magnetic Resonance in Medicine.